Categories: Wire Stories

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center. This is the first time that zurletrectinib will be evaluated in a clinical study of pediatric (2 to 12 years old) patients, after demonstrating good safety and efficacy in adult and adolescent patients (12 to 18 years old).

Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant TRKA with resistant mutations G595R or G667C. Zurletrectinib could overcome acquired resistance to the first-generation TRK inhibitors.

InnoCare has been advancing the registrational trial of zurletrectinib in China and is expecting to submit the new drug application in the second half of 2024. An overall response rate (ORR) of 80-90%, indicating favorable efficacy, was observed in adult patients with various cancers carrying NTRK gene fusion who received dosages of 8 mg or more.

Dr. Jasmine, the Co-founder, Chairwoman, and CEO of InnoCare, said, “NTRK gene fusion is a driving factor for various adult and pediatric cancers. It is inspiring that we continue to make positive progress in our clinical research of zurletrectinib for patients of different ages with NTRK gene fusion. We expect to see our innovative assets benefit solid tumor patients in the near future.”

In some rare tumor types, such as congenital infantile fibrosarcoma, the incidence of NTRK gene fusion is as high as 90%. NTRK gene fusion is associated with at least 19 tumor types in adults and children, including lung cancer, colorectal cancer, breast cancer, pancreatic cancer and melanoma.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

Contacts

Media
Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investors
86-10-66609999

ir@innocarepharma.com

Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.

Recent Posts

Cyclone Akvan Grounds 20 Flights at Ranchi Airport as Visibility Drops to 1,000 Metres

Cyclone Akvan grounded air travel across Jharkhand on Saturday after severe visibility drops forced Birsa…

60 minutes ago

Mourinho’s Tactical Restraint Cannot Hide Vinícius Júnior’s Match-Winning Reality at Real Madrid

The real question facing Real Madrid under Jose Mourinho isn't how to handle squad rotation,…

2 hours ago

Kylian Mbappé’s Real Power Lies Beyond His Record 400-Goal Sprint

The real weight of Kylian Mbappé's global stature isn't measured merely by his pitch dominance,…

3 hours ago

Dhanush Registers Career-Best Opening with OM, But Script Weaknesses Threaten Weekend Momentum

A record-breaking career opening isn't a guarantee of theatrical longevity when narrative flaws emerge on…

5 hours ago

Why Kevin Vallejos Faces a Tactical Trap Against Aljamain Sterling at UFC Qatar

The biggest obstacle standing between Kevin Vallejos and a UFC featherweight title shot isn't Aljamain…

6 hours ago

PSG Travel to Nice as Ligue 1 Top-Two Form Teams Clash at Allianz Riviera

Paris Saint-Germain will look to solidify their spot at the top of the Ligue 1…

7 hours ago